Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

'New standard of care’ for CLL in younger patients

Shanafelt TD et al. ASH 2018, Abstract LBA-4

Key clinical point: Ibrutinib-rituximab (IR) may be a new standard of care for patients aged 70 or younger with untreated chronic lymphocytic leukemia.

Major finding: The hazard ratio for disease progression with IR versus FCR was 0.35 (P less than .00001).

Study details: Interim analysis of a phase 3 trial in 529 patients aged 70 or younger with newly diagnosed CLL.

Disclosures: The trial was sponsored by the National Cancer Institute with additional support from Pharmacyclics. Dr. Shanafelt reported patents and royalties from the Mayo Clinic, and research funding from Celgene, GlaxoSmithKline, Genentech, Abbvie, Pharmacyclics, and Janssen.

Read the Article.

Citation:

Shanafelt TD et al. ASH 2018, Abstract LBA-4

This Week's Must Reads

'New standard of care’ for CLL in younger patients, Shanafelt TD et al. ASH 2018, Abstract LBA-4

Mutation pegged as CLL resistance mechanism to venetoclax, Blombery P et al. ASH 2018, Abstract LBA-7

Guidelines for primary central nervous system lymphoma, Fox et al. Br J Haematol. 2018 Nov 23 doi: 10.1111/bjh.15661

FLYER evaluates number of R-CHOP cycles in DLBCL, Poeschel V et al. ASH 2018, Abstract 781

Ibrutinib-based therapy improves survival in CLL, Woyach JA et al. ASH 2018, Abstract 6

Must Reads in Aggressive Lymphomas

'New standard of care’ for CLL in younger patients, Shanafelt TD et al. ASH 2018, Abstract LBA-4

Mutation pegged as CLL resistance mechanism to venetoclax, Blombery P et al. ASH 2018, Abstract LBA-7

Guidelines for primary central nervous system lymphoma, Fox et al. Br J Haematol. 2018 Nov 23 doi: 10.1111/bjh.15661

FLYER evaluates number of R-CHOP cycles in DLBCL, Poeschel V et al. ASH 2018, Abstract 781

Ibrutinib-based therapy improves survival in CLL, Woyach JA et al. ASH 2018, Abstract 6